Felicity Swan

Felicity Swan is an accomplished pharma marketing professional with a remarkable history of driving exceptional results in marketing, sales, and life cycle management.

With a focus on the APAC region, Felicity possesses the confidence and skills to spearhead launch campaigns and oversee direct and cross-functional teams.

Her notable achievements include the successful relaunch of Saizen (a growth hormone) in the competitive Australian market and the strategic pre-launch planning for Merck KGaA's premier Neurology product.

Felicity is driven by surpassing targets and motivating teams to realize their full potential.

Her competencies span across strategic marketing leadership, financial acumen, project management, team leadership, and digital marketing initiatives such as website development, email campaigns, and digital opinion leader engagements.

Education-wise, Felicity holds an MBA from Macquarie Graduate School of Management, a Post Graduate Certificate in Diabetes Management from the University of Technology, Sydney, a Bachelor of Science in Nursing from Edith Cowan University, and a Bachelor of Science in Biomechanics from The University of Western Australia.

In terms of professional experience, Felicity has held key roles such as Director of Projects and Strategy Implementation at Astellas Pharma, Associate Director of Strategy in International Markets at Astellas Pharma, and various positions at AstraZeneca, Merck, Genzyme, and Baxter Healthcare focusing on marketing, government affairs, market access, and sales in the pharma industry.